Baseline patient characteristics
| . | All . | Group 0 . | Group 1 . | P . |
|---|---|---|---|---|
| Patients, n (%) | 66 (100) | 32 (48) | 34 (52) | |
| Age at diagnosis, median (range), y | 56 (16-78) | 48 (16-78) | 60 (26-77) | .3 (>60 vs <60) |
| Sex, M/F | 37/29 | 17/15 | 20/14 | |
| % BM blasts at diagnosis, median (range) | 78 (20-97) | 81 (21-94) | 70 (20-97) | |
| Cytogenetic risk, n (%) | .7 (favorable vs intermediate/adverse) | |||
| Favorable | 7 (10.6) | 4 (12.5) | 3 (8.8) | |
| Intermediate | 46 (69.7) | 20 (62.5) | 26 (76.5) | |
| Adverse | 13 (19.7) | 8 (25) | 5 (14.7) | |
| ELN, evaluable, n (%) | 60 (91) | 30 (93.8) | 30 (88.2) | .08 (favorable vs intermediate/adverse) |
| Favorable | 20 (33.3) | 7 (23.3) | 13 (43.3) | |
| Intermediate | 15 (25) | 7 (23.3) | 8 (26.7) | |
| Adverse | 25 (41.7) | 16 (53.3) | 9 (30) | |
| Response to iCT, n (%) | ||||
| CR | 45 (68.2) | 22 (68.8) | 23 (67.6) | |
| NR | 11 (16.7) | 6 (18.8) | 5 (14.7) | |
| n.e./death | 10 (15.2) | 4 (12.5) | 6 (17.6) | |
| AlloHSCT, n (%) | ||||
| No | 46 (69.7) | 20 (62.5) | 26 (76.5) | |
| Yes | 16 (24.2) | 11 (34.4) | 5 (14.7) | |
| n.a. | 4 (6) | 1 (3.1) | 3 (8.8) |
| . | All . | Group 0 . | Group 1 . | P . |
|---|---|---|---|---|
| Patients, n (%) | 66 (100) | 32 (48) | 34 (52) | |
| Age at diagnosis, median (range), y | 56 (16-78) | 48 (16-78) | 60 (26-77) | .3 (>60 vs <60) |
| Sex, M/F | 37/29 | 17/15 | 20/14 | |
| % BM blasts at diagnosis, median (range) | 78 (20-97) | 81 (21-94) | 70 (20-97) | |
| Cytogenetic risk, n (%) | .7 (favorable vs intermediate/adverse) | |||
| Favorable | 7 (10.6) | 4 (12.5) | 3 (8.8) | |
| Intermediate | 46 (69.7) | 20 (62.5) | 26 (76.5) | |
| Adverse | 13 (19.7) | 8 (25) | 5 (14.7) | |
| ELN, evaluable, n (%) | 60 (91) | 30 (93.8) | 30 (88.2) | .08 (favorable vs intermediate/adverse) |
| Favorable | 20 (33.3) | 7 (23.3) | 13 (43.3) | |
| Intermediate | 15 (25) | 7 (23.3) | 8 (26.7) | |
| Adverse | 25 (41.7) | 16 (53.3) | 9 (30) | |
| Response to iCT, n (%) | ||||
| CR | 45 (68.2) | 22 (68.8) | 23 (67.6) | |
| NR | 11 (16.7) | 6 (18.8) | 5 (14.7) | |
| n.e./death | 10 (15.2) | 4 (12.5) | 6 (17.6) | |
| AlloHSCT, n (%) | ||||
| No | 46 (69.7) | 20 (62.5) | 26 (76.5) | |
| Yes | 16 (24.2) | 11 (34.4) | 5 (14.7) | |
| n.a. | 4 (6) | 1 (3.1) | 3 (8.8) |
All patients (All) and patients stratified according to their flow cytometry NKRL group (Group 0, NK receptor ligand inhibitory pattern; and Group 1, NKRL activating pattern) are shown separately.
BM, bone marrow; CR, complete remission; F, female; iCT, induction chemotherapy; M, male; n.a., not available; n.e., not evaluable; NR, nonresponse.